CriticalSNRI×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and duloxetine inhibits serotonin and noradrenaline reuptake. The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with duloxetine (St John's wort SmPC, AEMPS, section 4.5). The duloxetine SmPC also states that adverse reactions may be more common with St John's wort and lists it among serotonergic agents (duloxetine SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). There is also a second route: St John's wort induces the enzyme CYP1A2 (St John's wort SmPC, AEMPS, section 4.5), and in the liver CYP1A2 and CYP2D6 convert duloxetine to inactive metabolites (duloxetine SmPC, EMA, section 5.2). Smokers, in whom CYP1A2 is induced, have duloxetine plasma levels almost 50% lower (duloxetine SmPC, EMA, section 4.5). The documents give no data on how St John's wort changes them.
Symptoms
According to the duloxetine label of the US Food and Drug Administration (FDA), St John's wort increases the risk of serotonin syndrome, a potentially life-threatening condition. Signs include mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (FDA duloxetine label, section 5.4). In its most severe form the syndrome can resemble neuroleptic malignant syndrome, with fever, muscle rigidity, raised serum creatine kinase, rapid fluctuation of vital signs and mental status changes (duloxetine summary of product characteristics, European Medicines Agency, EMA, section 4.4).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, and its interaction table names duloxetine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The duloxetine SmPC is less strict and recommends caution when duloxetine is used with St John's wort (duloxetine SmPC, European Medicines Agency, EMA, section 4.5). If the two have nevertheless been taken together, observe the patient carefully for signs of serotonin syndrome, particularly at the start of treatment and after dose increases (duloxetine SmPC, EMA, section 4.4; duloxetine label, US Food and Drug Administration, FDA, section 7.14). If serotonin syndrome occurs, consider stopping duloxetine and/or the other serotonergic medicines (FDA duloxetine label, section 7.14). No document says how long to wait between stopping St John's wort and starting duloxetine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Cymbalta 30 mg cápsulas duras gastrorresistentes – ficha técnica (texto EMA en CIMA) (2026)– EMA SmPC vía AEMPS CIMA, nº 04296001 (EU/1/04/296), secciones 4.4 y 4.5
- FDA: Duloxetine delayed-release capsules (duloxetine) prescribing information (2026)– FDA, DailyMed, Lupin Pharmaceuticals, setid 829a4f51-c882-4b64-81f3-abfb03a52ebe, revised 05/2026, sections 4, 5.2, 5.4, 5.5, 7.1–7.17 and 12.2
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5